Media Coverage

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing [Microdose]

By November 5, 2026No Comments

For a drug designed to change how the brain functions, reaching the brain is only part of the story. Understanding what happens once it gets there can help shape the path into clinical trials. That is the focus of new preclinical findings announced by Enveric Biosciences on November 4. The company reported that its lead neuroplastogen candidate, EB-003, produced measurable changes in brain-wave activity in mice, with a pattern differentiated from the classic psychedelic dimethyltryptamine, or DMT.

Full Article >>